NCPA members will speak on compounding at annual FDA listening session next week

On Jun 15, NCPA staff Steve Postal and NCPA members Steve Hoffart and Cheri Garvin will participate in the FDA’s annual listening session by speaking about compounding. Hoffart and Garvin will each be giving 5-minute statements. NCPA submitted its written statement for the record ahead of the listening session on compounding, which covers concerns with GFI #256 (compounding animal drugs from bulk substances), as well as patient access to compounded bioidentical hormone therapy, drug shortages, and adverse event reporting. To keep up to date with key compounding policies and NCPA advocacy, click here.